Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H13N3O2S |
| Molecular Weight | 299.348 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2N=C(NC(=O)NC3=CC=CC=C3)SC2=C1
InChI
InChIKey=JHBWYQRKOUBPCA-UHFFFAOYSA-N
InChI=1S/C15H13N3O2S/c1-20-11-7-8-12-13(9-11)21-15(17-12)18-14(19)16-10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)
Frentizole, a nontoxic antiviral and immunosuppressive
agent, was used clinically in rheumatoid arthritis and systemic
lupus erythematosus. Frentizole was more effective in suppressing human lymphocytes responding to Con A and PWM, than it was in cells activated by PHA, specific antigen, or alloantigen. Methylprednisolone, on the other hand, was more inhibitory for cells stimulated by PHA, specific antigen, or alloantigen. Frentizole, even at super immunosuppressive doses, does not predispose the hose (mice) to Pseudomonas aeruginosa, Candida albicans, herpes simplex virus, or Ann Arbor influenza virus. Frentizole is an inhibitor of the Aβ-ABAD interaction.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Aβ-ABAD/HSD17B10 interaction |
200.0 µM [IC50] | ||
Target ID: GO:0002456 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseSystemic Lupus Erythematosus |
|||
| Primary | Unknown Approved UseRheumatoid Arthritis |
Sample Use Guides
Eleven steroid-treated patients with active systemic lupus erythematosus received frentizole (150-350 mg/day) in combination with stable or decreasing doses of prednisone in an open label trial.
Route of Administration:
Oral
Frentizole (500 ng/ml) inhibited thymidine incorporation into DNA most effectively when added to human lymphocyte cultures at the same time as the addition of the mitogen. Frentizole (500 ng/ml) markedly inhibited the response to Con A (% inhibition, corporation was dose dependent with 125 ng/ml of Frentizole sufficient to inhibit significantly the response of all three mitogens. Frentizole (62.5 ng/ml) maximally inhibited uridine incorporation.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3920
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY | |||
|
SUB07815MIG
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY | |||
|
33334
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY | |||
|
C013997
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY | |||
|
C167023
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY | |||
|
DTXSID5046279
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY | |||
|
CHEMBL128988
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY | |||
|
26130-02-9
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY | |||
|
7EY946394I
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY | |||
|
100000080447
Created by
admin on Fri Dec 15 17:25:13 UTC 2023 , Edited by admin on Fri Dec 15 17:25:13 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
